目的:观察针灸治疗对H_(22)荷瘤小鼠CD4^+CD25^+Treg细胞(CD4^+CD25^+regulatory T cells)体外增殖的影响和针灸血清刺激下的CD4^+CD25^+Treg细胞的体外增殖变化,探讨针灸及其血清对荷瘤小鼠免疫调节细胞的干预作用。方法:48只小鼠随机...目的:观察针灸治疗对H_(22)荷瘤小鼠CD4^+CD25^+Treg细胞(CD4^+CD25^+regulatory T cells)体外增殖的影响和针灸血清刺激下的CD4^+CD25^+Treg细胞的体外增殖变化,探讨针灸及其血清对荷瘤小鼠免疫调节细胞的干预作用。方法:48只小鼠随机分为电针治疗组、艾灸治疗组、肿瘤对照组、正常对照组。采用H_(22)肿瘤细胞移植性实体瘤模型,电针和艾灸"大椎"治疗后,磁珠分离CD4^+CD25^+Treg细胞,氚标记胸腺嘧啶核苷掺入法观察不同组小鼠CD4^+CD25^+Treg细胞体外增殖能力和针灸血清对CD4^+CD25^+ Treg细胞体外增殖的影响。结果:肿瘤对照组CD4^+CD25^+Treg细胞增殖水平比正常对照组明显增高(P<0.05);电针治疗组和艾灸治疗组CD4^+CD25^+Treg细胞增殖水平与肿瘤对照组比较均明显降低(P<0.01)。电针治疗组和艾灸治疗组1:1、1:8稀释度血清刺激正常小鼠CD4^+CD25^+Treg细胞体外增殖,较正常对照、肿瘤对照组血清显著增高(P<0.05),各组1:16、1:32稀释度血清对Treg细胞作用的差别无统计学意义(P>0.05)。结论:针灸治疗能下调荷瘤小鼠CD4^+CD25^+Treg细胞体外增殖能力。不同浓度针灸血清体外刺激CD4^+CD25^+Treg细胞增殖表现出不一致的效应。展开更多
目的探讨Treg及Th1/Th2类细胞因子在晚期肺癌肿瘤免疫抑制中的作用。方法选取100例初治晚期肺癌患者及50例健康自愿者。采用流式细胞术检测其外周血中Treg、Th1类细胞因子(IFN-γ、IL-2、TNF-a)、Th2类细胞因子(IL-4、IL-6、IL-10)水平...目的探讨Treg及Th1/Th2类细胞因子在晚期肺癌肿瘤免疫抑制中的作用。方法选取100例初治晚期肺癌患者及50例健康自愿者。采用流式细胞术检测其外周血中Treg、Th1类细胞因子(IFN-γ、IL-2、TNF-a)、Th2类细胞因子(IL-4、IL-6、IL-10)水平,同时分析CD4^+CD25^+Treg与Th1/Th2类细胞因子之间的相关性。结果 (1)晚期肺癌患者外周血中Treg为(11.12±5.83)%,高于健康对照组(7.46±3.07)%,差异有统计学意义(P=0.003);(2)化疗前肺癌患者外周血中Treg为(11.12±5.83)%,明显高于化疗后(6.45±3.74)%,差异有统计学意义(P<0.001);(3)晚期肺癌患者与正常对照组Th1/Th2类细胞因子水平分别为:IFN-γ(8.56±3.62 vs 10.79±3.27,P=0.049)、IL-2(8.48±2.87 vs10.22±4.03,P=0.03)、TNF-a(6.18±2.67vs8.14±2.87,P=0.007)、IFN-γ/IL-4(3.33±1.44 vs 4.09±1.00,P=0.028)、IL-4(3.17±1.19 vs 2.45±0.43,P<0.001)、IL-6(3.88±2.08 vs 2.33±0.88,P<0.001)、IL-10(3.64±1.73 vs2.54±1.08,P=0.008),其中Th2类因子水平明显升高,差异有统计学意义(P均<0.05);(4)CD4^+CD25^+Treg与Th1类细胞因子IFN-γ、TNF-a、IL-2及IL-6无相关性(P均>0.05);与Th1/Th2(γ=-0.273,P=0.003)呈负相关;与Th2类细胞因子IL-4(γ=0.237,P=0.009)、IL-10(0.626,P<0.001)呈正相关(P均<0.05)。结论晚期肺癌患者CD4^+CD25^+Treg、Th2类细胞因子水平显著升高,Th1类细胞因子水平下降,它们共同导致肿瘤患者免疫抑制及肿瘤进展,监测其水平变化有助于判断肺癌患者疗效、预后,有效调控CD4^+CD25^+Treg及负性细胞因子水平可能是治疗肺癌的一个新策略。展开更多
CD4＋CD25＋FoxP3 ＋ regulatory T ceils （Tregs） are increased in patients with chronic hepatitis C, which may contribute to the sustained suppression of hepatitis C virus （HCV）-specific T-cell responses and viral p...CD4＋CD25＋FoxP3 ＋ regulatory T ceils （Tregs） are increased in patients with chronic hepatitis C, which may contribute to the sustained suppression of hepatitis C virus （HCV）-specific T-cell responses and viral persistence in HCV-infected individuals. We postulated that HCV core protein （HCVc） directly contributes to the expansion of Tregs in HCV-infected patients, and we provide evidence to support this hypothesis in the report. Peripheral blood mononuclear cells （PBMCs） and sera were collected from 87 treatment-naive chronic HCV-infected patients, CD4＋CD25＋ Tregs were measured by flow cytometry, and HCV RNA and HCVc levels were detected using qPCR and enzyme-linked immunosorbent assay （ELISA）, respectively. CD4＋, CD8＋, CD4＋CD25＋ and CD4＋CD25- T cells were purified from healthy donors and cultured with recombinant HCVc and Toll-like receptor （TLR） ligands. Flow cytometry was used to analyze cell proliferation, and ELISA was performed to measure cytokine production. In the 87 chronic HCV-infected patients, HCVc showed a significant correlation with HCV RNA and CD4＋CD25＋Tregs. Mechanistic studies showed that HCVc, together with anti-CD3 antibody, augmented CD4＋CD25＋ Treg proliferation, but inhibited CD4＋CD25- T-cell proliferation and IFN-γ production, in a dose-dependent and Treg-dependent manner. Moreover, unlike the TLR3 ligand （poly hC） and the TLR4 ligand （lipopolysaccharide, LPS）, the TLR2 ligand （lipoteichoic acid, LTA） and HCVc both inhibited TCR-induced CD4＋ T-cell proliferation and IFN-γ secretion in a Treg-dependent manner. These data indicate that HCVc, like other TLR2 ligands, triggers CD4＋CD25＋ Treg activation and expansion to inhibit host immune responses, which may play a critical role in viral persistence in HCV-infected patients.展开更多
文摘目的:观察针灸治疗对H_(22)荷瘤小鼠CD4^+CD25^+Treg细胞(CD4^+CD25^+regulatory T cells)体外增殖的影响和针灸血清刺激下的CD4^+CD25^+Treg细胞的体外增殖变化,探讨针灸及其血清对荷瘤小鼠免疫调节细胞的干预作用。方法:48只小鼠随机分为电针治疗组、艾灸治疗组、肿瘤对照组、正常对照组。采用H_(22)肿瘤细胞移植性实体瘤模型,电针和艾灸"大椎"治疗后,磁珠分离CD4^+CD25^+Treg细胞,氚标记胸腺嘧啶核苷掺入法观察不同组小鼠CD4^+CD25^+Treg细胞体外增殖能力和针灸血清对CD4^+CD25^+ Treg细胞体外增殖的影响。结果:肿瘤对照组CD4^+CD25^+Treg细胞增殖水平比正常对照组明显增高(P<0.05);电针治疗组和艾灸治疗组CD4^+CD25^+Treg细胞增殖水平与肿瘤对照组比较均明显降低(P<0.01)。电针治疗组和艾灸治疗组1:1、1:8稀释度血清刺激正常小鼠CD4^+CD25^+Treg细胞体外增殖,较正常对照、肿瘤对照组血清显著增高(P<0.05),各组1:16、1:32稀释度血清对Treg细胞作用的差别无统计学意义(P>0.05)。结论:针灸治疗能下调荷瘤小鼠CD4^+CD25^+Treg细胞体外增殖能力。不同浓度针灸血清体外刺激CD4^+CD25^+Treg细胞增殖表现出不一致的效应。
文摘目的探讨Treg及Th1/Th2类细胞因子在晚期肺癌肿瘤免疫抑制中的作用。方法选取100例初治晚期肺癌患者及50例健康自愿者。采用流式细胞术检测其外周血中Treg、Th1类细胞因子(IFN-γ、IL-2、TNF-a)、Th2类细胞因子(IL-4、IL-6、IL-10)水平,同时分析CD4^+CD25^+Treg与Th1/Th2类细胞因子之间的相关性。结果 (1)晚期肺癌患者外周血中Treg为(11.12±5.83)%,高于健康对照组(7.46±3.07)%,差异有统计学意义(P=0.003);(2)化疗前肺癌患者外周血中Treg为(11.12±5.83)%,明显高于化疗后(6.45±3.74)%,差异有统计学意义(P<0.001);(3)晚期肺癌患者与正常对照组Th1/Th2类细胞因子水平分别为:IFN-γ(8.56±3.62 vs 10.79±3.27,P=0.049)、IL-2(8.48±2.87 vs10.22±4.03,P=0.03)、TNF-a(6.18±2.67vs8.14±2.87,P=0.007)、IFN-γ/IL-4(3.33±1.44 vs 4.09±1.00,P=0.028)、IL-4(3.17±1.19 vs 2.45±0.43,P<0.001)、IL-6(3.88±2.08 vs 2.33±0.88,P<0.001)、IL-10(3.64±1.73 vs2.54±1.08,P=0.008),其中Th2类因子水平明显升高,差异有统计学意义(P均<0.05);(4)CD4^+CD25^+Treg与Th1类细胞因子IFN-γ、TNF-a、IL-2及IL-6无相关性(P均>0.05);与Th1/Th2(γ=-0.273,P=0.003)呈负相关;与Th2类细胞因子IL-4(γ=0.237,P=0.009)、IL-10(0.626,P<0.001)呈正相关(P均<0.05)。结论晚期肺癌患者CD4^+CD25^+Treg、Th2类细胞因子水平显著升高,Th1类细胞因子水平下降,它们共同导致肿瘤患者免疫抑制及肿瘤进展,监测其水平变化有助于判断肺癌患者疗效、预后,有效调控CD4^+CD25^+Treg及负性细胞因子水平可能是治疗肺癌的一个新策略。
基金This work was supported by the Natural Science Foundation of China （81373143, to ZT） and by NIH （AI095097, to LS）. The funders had no role in the study design, data collection and analysis, decision to publish or preparation of the paper.
文摘CD4＋CD25＋FoxP3 ＋ regulatory T ceils （Tregs） are increased in patients with chronic hepatitis C, which may contribute to the sustained suppression of hepatitis C virus （HCV）-specific T-cell responses and viral persistence in HCV-infected individuals. We postulated that HCV core protein （HCVc） directly contributes to the expansion of Tregs in HCV-infected patients, and we provide evidence to support this hypothesis in the report. Peripheral blood mononuclear cells （PBMCs） and sera were collected from 87 treatment-naive chronic HCV-infected patients, CD4＋CD25＋ Tregs were measured by flow cytometry, and HCV RNA and HCVc levels were detected using qPCR and enzyme-linked immunosorbent assay （ELISA）, respectively. CD4＋, CD8＋, CD4＋CD25＋ and CD4＋CD25- T cells were purified from healthy donors and cultured with recombinant HCVc and Toll-like receptor （TLR） ligands. Flow cytometry was used to analyze cell proliferation, and ELISA was performed to measure cytokine production. In the 87 chronic HCV-infected patients, HCVc showed a significant correlation with HCV RNA and CD4＋CD25＋Tregs. Mechanistic studies showed that HCVc, together with anti-CD3 antibody, augmented CD4＋CD25＋ Treg proliferation, but inhibited CD4＋CD25- T-cell proliferation and IFN-γ production, in a dose-dependent and Treg-dependent manner. Moreover, unlike the TLR3 ligand （poly hC） and the TLR4 ligand （lipopolysaccharide, LPS）, the TLR2 ligand （lipoteichoic acid, LTA） and HCVc both inhibited TCR-induced CD4＋ T-cell proliferation and IFN-γ secretion in a Treg-dependent manner. These data indicate that HCVc, like other TLR2 ligands, triggers CD4＋CD25＋ Treg activation and expansion to inhibit host immune responses, which may play a critical role in viral persistence in HCV-infected patients.
